Nodality Snags Pfizer Deal to Improve Autoimmune R&D, Diagnostics

South San Francisco-based Nodality has spent five years honing an enabling technology for personalized medicine, which could help patients avoid wasteful treatments and improve the success rate in new drug R&D. Now it has persuaded New York-based Pfizer, the world’s biggest drugmaker, to buy into its vision.
Xconomy